glp 1 agonist cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies: Trends in Endocrinology & Metabolism EASD 2018: benefits of GIP/GLP-1

The vote on BPC-157 reflected the unusual makeup of the panel

PMID 21548867

In trials with patients with type 2 diabetes and overweight/obesity, after 16 weeks of treatment with Danuglipron, the high-dose (120 mg twice daily) group showed an average weight loss of 4.2 kg and a reduction in HbA1c levels by 1.2% compared to the placebo group

doi: 10.3390/nu10050541

Also, The National Institutes of Health and the Institute of Medicine have determined that no adverse effects have been established from excess amounts of B-12 in the body

It is particularly good at delivering these results as it targets all these areas